MedTrace Logo

Preoxygenation With Optiflow™ - the Effect of Speech on Lung Oxygenation.

NCT03766646 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2020-10-30

Study results available
· View outcomes & findings →

Summary

If a patient speaks during the process of preoxygenation with high-flow nasal oxygen via the Optiflow™ system, is the efficacy reduced as measured by end-tidal lung oxygen content?

Conditions

  • Unrecognized Condition

Interventions

DEVICE

Optiflow

45l.min oxygen

Sponsors & Collaborators

  • University Hospital Southampton NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Patrick Butler · Unvistery Hospital Southampton

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-10-18
Primary Completion
2018-11-16
Completion
2018-11-16

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03766646 on ClinicalTrials.gov